Raymond James & Associates Neurocrine Biosciences Inc Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Raymond James & Associates holds 62,446 shares of NBIX stock, worth $8.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

62,446

Previous 59,894 4.26%

Holding current value

$8.8 Million

Previous $8.25 Million 12.81%

% of portfolio

0.0%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$114.58 - $153.15 $292,408 - $390,838	2,552 Added 4.26%	62,446 $7.19 Million
Q2 2024 Jul 19, 2024	SELL	$130.86 - $143.19 $59,410 - $65,008	-454 Reduced 0.75%	59,894 $8.25 Million
Q1 2024 Apr 22, 2024	BUY	$130.4 - $143.74 $296,660 - $327,008	2,275 Added 3.92%	60,348 $8.32 Million
Q4 2023 Jan 16, 2024	SELL	$106.07 - $132.76 $55,580 - $69,566	-524 Reduced 0.89%	58,073 $7.65 Million
Q3 2023 Oct 24, 2023	SELL	$94.02 - $117.1 $88,284 - $109,956	-939 Reduced 1.58%	58,597 $6.59 Million
Q2 2023 Jul 25, 2023	SELL	$89.53 - $104.87 $1.68 Million - $1.97 Million	-18,758 Reduced 23.96%	59,536 $5.61 Million
Q1 2023 Apr 14, 2023	BUY	$94.11 - $123.02 $33,691 - $44,041	358 Added 0.46%	78,294 $7.92 Million
Q4 2022 Feb 08, 2023	BUY	$106.72 - $127.06 $612,999 - $729,832	5,744 Added 7.96%	77,936 $9.31 Million
Q3 2022 Oct 25, 2022	BUY	$92.03 - $107.81 $706,422 - $827,549	7,676 Added 11.9%	72,192 $7.67 Million
Q2 2022 Aug 12, 2022	SELL	$75.79 - $100.07 $1.15 Million - $1.52 Million	-15,230 Reduced 19.1%	64,516 $6.29 Million
Q1 2022 May 11, 2022	BUY	$72.45 - $94.81 $1.02 Million - $1.34 Million	14,089 Added 21.46%	79,746 $7.48 Million
Q4 2021 Feb 08, 2022	SELL	$79.65 - $106.22 $6.98 Million - $9.31 Million	-87,675 Reduced 57.18%	65,657 $5.59 Million
Q3 2021 Nov 02, 2021	SELL	$86.18 - $99.03 $777,515 - $893,448	-9,022 Reduced 5.56%	153,332 $14.7 Million
Q2 2021 Aug 11, 2021	SELL	$89.43 - $102.27 $1.7 Million - $1.94 Million	-19,009 Reduced 10.48%	162,354 $15.8 Million
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $757,655 - $1.03 Million	-8,652 Reduced 4.55%	181,363 $17.6 Million
Q4 2020 Feb 12, 2021	BUY	$86.91 - $108.33 $6.82 Million - $8.51 Million	78,516 Added 70.42%	190,015 $18.2 Million
Q3 2020 Nov 04, 2020	BUY	$96.16 - $135.15 $305,596 - $429,506	3,178 Added 2.93%	111,499 $10.7 Million
Q2 2020 Jul 28, 2020	BUY	$85.09 - $130.36 $924,077 - $1.42 Million	10,860 Added 11.14%	108,321 $13.2 Million
Q1 2020 Apr 21, 2020	BUY	$75.11 - $113.76 $271,973 - $411,924	3,621 Added 3.86%	97,461 $8.44 Million
Q4 2019 Feb 12, 2020	BUY	$86.8 - $118.57 $333,485 - $455,545	3,842 Added 4.27%	93,840 $10.1 Million
Q3 2019 Nov 07, 2019	BUY	$83.82 - $101.5 $1.26 Million - $1.52 Million	14,973 Added 19.96%	89,998 $8.11 Million
Q2 2019 Aug 06, 2019	BUY	$72.24 - $91.27 $1.29 Million - $1.63 Million	17,853 Added 31.23%	75,025 $6.33 Million
Q1 2019 May 06, 2019	BUY	$69.31 - $91.53 $1.92 Million - $2.54 Million	27,732 Added 94.2%	57,172 $5.04 Million
Q4 2018 Feb 11, 2019	SELL	$68.32 - $124.36 $602,514 - $1.1 Million	-8,819 Reduced 23.05%	29,440 $2.1 Million
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $2.76 Million - $3.51 Million	27,866 Added 268.12%	38,259 $4.7 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $83,507 - $117,542	1,109 Added 11.95%	10,393 $1.02 Million
Q1 2018 May 14, 2018	BUY	$75.88 - $92.43 $11,989 - $14,603	158 Added 1.73%	9,284 $770,000
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $793,081 - $1.05 Million	-13,550 Reduced 59.75%	9,126 $708,000
Q3 2017 Nov 13, 2017	BUY	$47.97 - $61.28 $736,147 - $940,402	15,346 Added 209.36%	22,676 $1.39 Million
Q2 2017 Aug 14, 2017	BUY	N/A	7,330	7,330 $337,000

Others Institutions Holding NBIX

# of Institutions

627

Shares Held

94M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Neurocrine Biosciences Inc Transaction History